Holen Sie sich die Stockscreener-App
21.71
2.25%
-0.50
Handel nachbörslich:
21.29
-0.42
-1.93%
Schlusskurs vom Vortag:
$22.21
Offen:
$21.55
24-Stunden-Volumen:
606.40K
Relative Volume:
1.08
Marktkapitalisierung:
$1.07B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-91.76M
KGV:
-3.9805
EPS:
-5.4541
Netto-Cashflow:
$-94.89M
1W Leistung:
-0.78%
1M Leistung:
-13.09%
6M Leistung:
+73.96%
1J Leistung:
+208.82%
1-Tages-Spanne:
$21.51
$22.81
1-Wochen-Bereich:
$21.51
$24.00
52-Wochen-Spanne:
$6.565
$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
Firmenname
Jade Biosciences Inc
Sektor
Branche
Telefon
(781) 312-3013
Adresse
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
21.71 | 1.10B | 0 | -91.76M | -94.89M | -5.4541 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Eingeleitet | BTIG Research | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-05-07 | Eingeleitet | Wedbush | Outperform |
| 2025-05-05 | Eingeleitet | Stifel | Buy |
| 2025-05-02 | Eingeleitet | TD Cowen | Buy |
| 2024-06-18 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-06-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-03-25 | Fortgesetzt | Jefferies | Buy |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-12-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-08-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-07-26 | Eingeleitet | Cowen | Outperform |
| 2021-07-26 | Eingeleitet | Evercore ISI | Outperform |
| 2021-07-26 | Eingeleitet | Jefferies | Buy |
| 2021-07-26 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Jade Biosciences Inc Aktie (JBIO) Neueste Nachrichten
Jade Biosciences doses first patient in JADE201 trial By Investing.com - Investing.com Canada
Rheumatoid arthritis antibody trial starts, first patient gets JADE201 - Stock Titan
Jade Biosciences doses first patient in IgAN phase 2 trial - Investing.com
Kidney disease in young adults: Jade starts Phase 2 JADE101 trial - Stock Titan
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy - GlobeNewswire
Jade Biosciences (JBIO) Falters in Mid-Session Trading: Support Levels in FocusIPO Entry Watch - Newser
Jade Biosciences Inc. (JBIO) Q1 2026 Earnings: EPS Miss Amid Continued Pre‑Revenue PhaseHot Momentum Watchlist - Newser
Jade Biosciences Inc. (JBIO) Q1 2026 Earnings: Clinical‑stage Biotech Misses Consensus as Cash Burn AcceleratesLive Trade Sharing - Newser
Jade Biosciences Inc. (JBIO) Holds Steady as Price Consolidates Near Key ResistanceCatalyst Driven Stocks - Newser
Jade Biosciences (JBIO) price target increased by 16.48% to 26.14 - MSN
[EFFECT] Jade Biosciences, Inc. SEC Filing - Stock Titan
Jade Biosciences IncProspectus filed for resale of up to 39,542,339 shares by selling stockholdersSEC filing - marketscreener.com
Jade Biosciences (JBIO) Declines -4.19% Amid Market Weakness 2026-05-15Expert Breakout Alerts - newser.com
Jade Biosciences (JBIO) Q1 2026 Disappoints — EPS $-0.57 Below $-0.49 ViewsForward Guidance - newser.com
Janus Henderson (JBIO) discloses 3,105,669-share, 6.3% holding in Jade Biosciences - Stock Titan
Jade Biosciences(JBIO) Stock Options Chain | Quotes & News - Moomoo
Jade Biosciences (JBIO) Q1 2026 Earnings Miss by Significant: Key TakeawaysHealthcare Earnings Report - Newser
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Jade Biosciences Price Target Raised to $34.00/Share From $24.00 by Wedbush - Moomoo
Jade Biosciences (NASDAQ:JBIO) Given New $34.00 Price Target at Wedbush - MarketBeat
Guggenheim Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $32 - Moomoo
Jade Biosciences (NASDAQ:JBIO) Cut to "Sell" at Wall Street Zen - MarketBeat
Analyst Reiterates Buy on Jade Biosciences as JADE101 Data and Multi-Asset Pipeline Catalysts Approach - TipRanks
Jade Biosciences: Buy Rating Reiterated on Strong Cash Runway, JADE101 Differentiation, and Unchanged $24 Price Target - TipRanks
TD Cowen Maintains Jade Biosciences(JBIO.US) With Buy Rating - Moomoo
Stifel Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Jade Biosciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Why Jade Biosciences (JBIO) looks attractive at current levels (Edges Lower) 2026-05-07Investment Community Signals - Newser
Jade Biosciences Inc may offer and sell up to $600 million of securitiesSEC filing - marketscreener.com
[S-3] Jade Biosciences, Inc. Shelf Registration Statement - Stock Titan
Jade Biosciences (NASDAQ: JBIO) posts $40.4M Q1 loss, ATM up to $200M - Stock Titan
Jade Biosciences (JBIO) ramps R&D with $40.4M loss and $311M cash - Stock Titan
Jade Biosciences (NASDAQ: JBIO) details Q1 2026 loss and cash - Stock Titan
2 small-cap stocks with big potential to buy under $30 - MSN
BRIEF-Jade Biosciences, Inc Q1 Cash & Investments USD 311.3 Million - TradingView
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update - ChartMill
JBIO SEC FilingsJade Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Jade Biosciences Reshapes Clinical Leadership As Valuation Debate Persists - Sahm
2 Small-Cap Stocks With Big Potential to Buy Under $30 - Barchart.com
Jade Biosciences (NASDAQ:JBIO) Stock Price Down 9.6%Here's What Happened - MarketBeat
What is HC Wainwright's Forecast for JBIO FY2030 Earnings? - MarketBeat
Jade Biosciences (NASDAQ: JBIO) outlines 2026 director votes, auditor and jury waiver - Stock Titan
Jade Biosciences (NASDAQ:JBIO) Sets New 1-Year HighHere's What Happened - MarketBeat
FY2028 Earnings Forecast for JBIO Issued By HC Wainwright - MarketBeat
Jade Biosciences stock hits 52-week high at 27.44 USD By Investing.com - Investing.com South Africa
Jade Biosciences (JBIO) price target increased by 10.24% to 28.82 - MSN
BlackRock (NYSE: JBIO) reports 2.3M JADE stake, 4.7% disclosed - Stock Titan
Jade Biosciences stock hits 52-week high at 27.44 USD - Investing.com
Jade Biosciences stock price target raised to $45 by H.C. Wainwright - Investing.com Canada
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $45 - Moomoo
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Finanzdaten der Jade Biosciences Inc-Aktie (JBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):